Results 21 to 30 of about 19,734 (164)

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes

Lipids in Health and Disease, 2017
Background Previous studies suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors have different effects on the lipid profile in patients with type 2 diabetes.
Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Tae-Seok Lim, Ki-Ho Song, Ki-Dong Yoo, Yu-Bae Ahn, Seung-Hyun Ko   +7 more
doaj   +1 more source

Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus

Journal of Diabetes Research, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are often used all over the world and exert various beneficial effects including glucose-lowering effect in many subjects with type 2 diabetes.
Masashi Shimoda, Maiko Miyoshi-Takai, Shintaro Irie, Akihito Tanabe, Atsushi Obata, Seizo Okauchi, Hidenori Hirukawa, Tomohiko Kimura, Kenji Kohara, Shinji Kamei, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto   +12 more
doaj   +1 more source

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis

BMC Cancer, 2019
Background Chemotherapy-induced alimentary mucositis (AM) is difficult to prevent and treatment is rarely effective. Recent study have been showed that glucagon-like peptide (GLP)-1 and GLP-2 has protective in chemotherapy-induced AM.
Jung Min Lee, In Kyung Yoo, Jae Min Lee, Seung Han Kim, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Yoon Tae Jeen, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um, Chang Duck Kim   +12 more
doaj   +1 more source

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease ...
Sung-Ho Kim, Jung-Hwa Yoo, Woo Je Lee, Cheol-Young Park   +3 more
doaj   +1 more source

Sitagliptin: the world’s first DPP-4 inhibitor

Медицинский совет, 2019
The prevalence of T2D is steadily increasing annually, which resulted in an active search for a way to control the disease. The last decade has seen a rise in the number of new groups of glucose-lowering drugs, which not only proved effective in the ...
N. A. Petunina, E. V. Goncharova, M. E. Telnova, L. V. Trukhina, N. S. Martirosyan   +4 more
doaj   +1 more source

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan

Drugs - Real World Outcomes
Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as a first-line therapy for type 2 diabetes in Japan. Precautions of the package inserts for ethical drugs containing DPP-4 inhibitors were revised for pemphigoid between 2016 and 2018.
Akina Takami, Gen Terashima, Takumi Tajima, Koki Yamashita, Ataru Igarashi   +4 more
doaj   +1 more source

Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis

Journal of Nepal Health Research Council, 2021
Drug-induced arthritis is not an uncommon scenario. DPP-4 inhibitors could potentially cause adverse-events mediated by cytokine-induced inflammation leading to arthritis. The activity of the DPP-4 enzyme could be inversely related to the development of
Binit Vaidya, Bhojraj Adhikari, Manisha Bhochhibhoya, Shweta Nakarmi   +3 more
doaj   +1 more source

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

Diabetes, Metabolic Syndrome and Obesity, 2020
Takeshi Osonoi, Miyoko Saito, Naoya Koda, Satako Douguchi, Takako Nakano, Kensuke Ofuchi, Makoto Katoh Naka Kinen Clinic, Ibaraki, JapanCorrespondence: Makoto KatohNaka Kinen Clinic, 745-5 Nakadai, Naka-Shi, Ibaraki 311-0113, JapanTel +81-29-353-2800Fax +
Osonoi T, Saito M, Koda N, Douguchi S, Nakano T, Ofuchi K, Katoh M   +6 more
doaj  

Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects

Molecular Metabolism, 2017
Objective: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) possess multiple bioactive isoforms that are rendered non-insulinotropic by the enzyme dipeptidyl peptidase-4 (DPP-4).
Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda, Jun Honjo, Hidemitsu Sakagami, Hiroya Kitsunai, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Timothy J. Kieffer, Masakazu Haneda   +10 more
doaj   +1 more source

Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data

BMC Medicine
Background Diabetes mellitus increases the risk of developing tuberculosis (TB) and negatively affects TB treatment outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in glycemic control but can also modulate immune pathways involved in immune ...
Yi-Geng Chen, James Cheng-Chung Wei, Fu-Shun Yen, Chen-Yu Sung, Yu-Han Huang, Teng-Shun Yu, Fuu-Jen Tsai, Chii-Min Hwu, Chih-Cheng Hsu   +8 more
doaj   +1 more source